Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Retrospective analysis of a cohort of participants involved in a randomised controlled trial (Lung Health Study), with annual follow up for 5 years.
10 clinical centres in North America.*
5887 adults aged 35–60 years, who smoked and had evidence of early chronic obstructive pulmonary disease (ie, had an FEV1/FVC [forced expiratory volume at 1 sec/forced vital capacity] interval of ≤70%, and an FEV1 of 55–90% of predicted normal).
Assessment of risk factors
Smoking status was assessed at baseline and at 5 annual visits thereafter. Participant reports of abstinence were confirmed by salivary cotinine concentrations (<20 ng/ml) or if nicotine substitution therapy was used, by CO concentrations (<10 ppm in end tidal …
Sources of funding: Division of Lung Diseases of the National Heart, Lung, and Blood Institute; Boehringer Ingelheim Pharmaceutical, Marion Merrell Dow, and Merrell Dow Pharmaceuticals (Canada) contributed drugs used by the study.
For correspondence: Dr R P Murray, Section of Clinical Epidemiology and Outcome Evaluation, Room MS754, Health Sciences Centre, University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada. Fax +1 204 789 3905.
↵* Anthonisen NR, Connett JE, Kiley JP, et al for the Lung Health Study Research Group. JAMA 1994;272:1497–505.